Loading...
•
Jun 30, 2021
Centessa Q2 2021 Earnings Report
Centessa reported financial results for the second quarter ended June 30, 2021, and provided a review of recent accomplishments.
Key Takeaways
Centessa Pharmaceuticals announced second quarter 2021 financial results, highlighting the successful completion of an initial public offering, which raised gross proceeds of $379.5 million. The company is advancing its portfolio of 16 clinical and preclinical programs and has strengthened its leadership team with key industry executives.
Successfully completed an initial public offering raising gross proceeds of $379.5 million.
Centessa leadership team strengthened through appointment of key industry executives.
Programs across Centessa portfolio continue to progress, with new data releases and/or trial initiations anticipated from ApcinteX, Palladio, Z-Factor and Pega-One in the second half of 2021.
Cash and cash equivalents were $613.8 million as of June 30, 2021.
Centessa
Centessa
Forward Guidance
Based on the current, non-risk-adjusted operating plan, the Company expects the cash and cash equivalents as of June 30, 2021, to fund its operations until the end of 2023.